Bolt Biotherapeutics, Inc. (BOLT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-12

Key Insights

Company released Q1 2026 financial results and business update on May 12, 2026, indicating continued operational reporting and transparency with investors.
CEO William P. Quinn serves as both President and Chief Financial Officer, suggesting a lean management structure typical of emerging growth companies that may limit segregation of duties.
The filing is furnished rather than filed, meaning the press release and financial information are not subject to liability under Securities Act sections 11 and 12(a)(2), reducing disclosure obligations for this earnings announcement.
As a Nasdaq Capital Market listed emerging growth company, Bolt has elected not to use extended transition periods for new accounting standards, indicating a commitment to full compliance with current standards.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-12

Bolt Biotherapeutics reported its Q4 2025 and full-year 2025 financial results, indicating the company's ongoing progress and development of its pipeline.
The company did not provide any guidance or updates on key clinical programs, which may raise some uncertainty among investors about the near-term outlook.
As an emerging growth company, Bolt Biotherapeutics has the option to take advantage of extended transition periods for complying with new or revised financial accounting standards, which could impact financial reporting and transparency.

Other reports for Bolt Biotherapeutics, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.